DDR2, ERBB2, and NTRK1 inhibitors have been proven effective against primary tumors harboring DDR2 or ERBB2 mutations or NTRK1 rearrangements, including NSCLC tumors.49 This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.